Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890370 | 1.00 | CES2 (0.43) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21391822 | 0.90 | CES2 (0.45) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL126540 | 0.90 | — | — | |
| SCHEMBL21391916 | 0.88 | CES2 (0.50) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21391917 | 0.88 | CES2 (0.43) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14273180 | 0.88 | CES2 (0.50) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2154406 | 0.87 | ACE (0.36) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21391824 | 0.85 | CES2 (0.55) | CES2CES1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL101983 | 0.84 | — | — | |
| SCHEMBL13397790 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165823-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | CURA THERAPEUTICS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20210052529-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | CURA THERAPEUTICS, LLC | 2021-02-25 | — | — | US | disclosed |
| EP-3099692-B9 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3521292-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3099692-B1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015110935-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | CES2 921/4885CES1 1033/4885CHRNB2 3585/4885 |
| US-20230165823-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | SLC16A1, SLC10A1, SLC16A7 | CES2 1837/4885CES1 479/4885CHRNB2 2551/4885 |
| US-10391182-B2 | Bifunctional cytotoxic agents | PAICS, CYTH3, CYTH2 | CES2 921/4885CES1 1033/4885CHRNB2 3585/4885 |
| US-20210052529-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | SLC16A1, SLC10A1, SLC16A7 | CES2 1837/4885CES1 705/4885CHRNB2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.